[{"from": "human", "value": "Provide a description of this molecule. [C][O][C][=C][C][=Branch2][Ring1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][/C][=C][\\C][C][C][N][=C][/-Ring1][=Branch1][C][=C][N][=C][C][=C][Ring1][=Branch1][O][C]"}, {"from": "gpt", "value": "The molecule is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551)."}]